Analgesics use and ESRD in younger age: a case-control study

BMC Nephrology

Table 4 Risk of ESRD and cumulative lifetime dose of Paracetamol, ASA, and substances containing neither ASA nor Paracetamol (mainly Ibuprofen) in any combination (mono- or combi) versus low use¹

	Dose (tertiles)	Range (grams)	Cases	Controls	OR (95% CI)
No/rare use			546	2030	1.0 (referent)
ASA	I	< 50	96	431	0.96 (0.60–1.54)
	II	50–162	77	443	0.77 (0.46–1.27)
	III	163+	114	432	1.07 (0.64–1.77)
Paracetamol	I	< 17	61	297	n.d.²
	II	17–74	65	304	0.95 (0.63–1.42)
	III	75+	77	296	1.11 (0.74–1.67)
Other	I	< 12	38	208	0.66 (0.41–1.08)
	II	12–73	47	215	0.79 (0.50–1.23)
	III	74+	63	209	n.d.²

¹ Standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime. Unmatched analysis; Adjustment for family history, soldering fumes, solvents, education, and for age, sex, country. Adjustment for confounding by all other analgesic combinations.
² dropped due to collinearity
n.d. = no data

ISSN: 1471-2369